natgillin/translations-raw huggingface dataset:
Rod pumping system according to claim 3, characterized in that the crosslinked polyethylene is a crosslinked high density polyethylene (HDPE) having a density of 940 - 964 kg/m3. 
Sustav crpljenja sa šipkom prema zahtjevu 3, naznačen time da umreženi polietilen je umreženi polietilen visoke gustoće (HDPK) koji ima gustoću od 940 - 964 kg/m3.
Rod pumping system according to any one of the preceding claims, characterized in that the crosslinked polyethylene has a crosslinking degree of 20-90%. 
Sustav crpljenja sa šipkom prema bilo kojem od prethodnih zahtjeva, naznačen time da umreženi polietilen ima stupanj umreženosti od 20-90%.
Rod pumping system according to any one of the preceding claims, characterized in that the well tubing is an oil well tubing. 
Sustav crpljenja sa šipkom prema bilo kojem od prethodnih zahtjeva, naznačen time da cijev bušotine je cijev naftne bušotine.
Panel as claimed in claim 1 characterized in that it includes a suitably shaped strengthening metal lath and having mesh openings suitable to receive said transparent to light material. 
Ploča prema zahtjevu 1, naznačena time što sadrži podesno oblikovani metalni nosač ojačanje i što ima okanca - otvore koji su prilagođeni za prihvat spomenutog materijala prozirnog za svijetlost.
Positioning in an orderly arrangement within a formwork a plurality of elements of said transparent to light material, 
postavljanjem u okvir u željenom rasporedu mnoštva elemenata od spomenutog materijala prozirnog za svijetlost,
During the time period from the beginning to the end of the mortar setting, taking out said cores from said formwork setting free said thus formed openings, 
izvlačenjem spomenutih jezgara iz spomenutog okvira tokom vremenskog razdoblja od početka do kraja vezivanja morta, čime se oslobađaju spomenuti otvori formirani na ovaj način,
Allowing the mortar and the transparent to light material to harden to afford said panel, and taking out the finished panel from the formwork. 
ostavljanjem morta i materijala prozirnog za svijetlost da očvrsnu da se dobije spomenuta ploča, te vađenjem gotove ploče iz okvira.
CY is a substituted or unsubstituted phenyl, wherein if CY is a substituted phenyl then the phenyl is substituted with 1 or 2 RC. 
CY je supstituirani ili nesupstituirani fenil, gdje ako je CY supstituirani fenil, tada je fenil supstituiran s 1 ili 2 RC.
A compound of any one of claims 1 to 11 or a pharmaceutically acceptable salt thereof for use in a method of treating or preventing lung fibrosis, asthma, chronic obstructive pulmonary disease (COPD), renal fibrosis, acute kidney injury, chronic kidney disease, liver fibrosis, skin fibrosis, fibrosis of the gut, breast cancer, pancreatic cancer, ovarian cancer, prostate cancer, glioblastoma, bone cancer, colon cancer, bowel cancer, head and neck cancer, melanoma, multiple myeloma, chronic lymphocytic leukemia, cancer pain, tumor metastasis, transplant organ rejection, scleroderma, ocular fibrosis, age related macular degeneration (AMD), diabetic retinopathy, collagen vascular disease, atherosclerosis, Raynaud's phenomenom, or neuropathic pain in a mammal. 
Spoj prema bilo kojem od zahtjeva 1 do 11 ili njegova farmaceutski prihvatljiva sol za uporabu u postupku liječenja ili prevencije plućne fibroze, astme, kronične opstruktivne plućne bolesti (KOPB), fibroze bubrega, akutne ozljede bubrega, kronične bolesti bubrega, fibroze jetre, kožne fibroze, fibroze crijeva, raka dojke, raka gušterače, raka jajnika, raka prostate, glioblastoma, raka kostiju, raka kolona, raka crijeva, raka glave i vrata, melanoma, multiplog mijeloma, kronične limfocitne leukemije, boli kod raka, metastaza tumora, odbacivanja transplantiranog organa, skleroderme, očne fibroze, makularne degeneracije povezane s dobi (AMD), dijabetičke retinopatije, kolagene vaskularne bolesti, ateroskleroze, Raynaud-ovog fenomena ili neuropatske boli u sisavaca.
The method of claim 1, wherein the xerostomia is associated with head and neck cancer. 
Betanekol za uporabu prema zahtjevu 1, pri čemu je kserostomija povezana s rakom glave i vrata.
The method of claim 1, wherein the xerostomia is associated with cancer chemotherapy treatment. 
Betanekol za uporabu prema zahtjevu 1, pri čemu je kserostomija povezana s kemoterapijskim liječenjem raka.
The method of claim 1, wherein the xerostomia is associated with Sjogren's syndrome. 
Betanekol za uporabu prema zahtjevu 1, pri čemu je kserostomija povezana sa Sjogrenovim sindromom.
The method of claim 1, wherein the xerostomia is associated with late-stage cancer. 
Betanekol za uporabu prema zahtjevu 1, pri čemu je kserostomija povezana s rakom u kasnoj fazi.
at least one mixing unit; 
barem jednu jedinicu za miješanje;
contained module according to claim 1, wherein the module has a level of containment below 100 mcg/m3, preferably below 10 mcg/m3. 
Zatvoreni modul prema zahtjevu 1, gdje je modul zatvoren tako da je propusnost manja od 100 mcg/m3, poželjno manja od 10 mcg/m3.
A contained module according to claim 4, wherein the control unit is adapted to control the speed of the tablet press. 
Zatvoreni modul prema zahtjevu 4, gdje je kontrolna jedinica prilagođena da kontrolira briznu preše za tablete.
mixing the material stream comprising the API and the excipient in said at least one mixing unit; 
miješanje pokretnog (protočnog) materijala koji sadrži API i pomoćnu tvar u barem jednoj jedinici za miješanje;
The method of claim 11 or 12, whereby a drying step is carried out before supplying the material stream to the tablet press. 
Postupak prema zahtjevu 11 ili 12, gdje se korak sušenja provodi prije snabdijevanja pokretnog materijala u prešu za tablete.
An impact pad (20) according to claim 1 wherein the first and second ends (24, 26) of the at least one channel (22) are vertically aligned in the plane of the sidewall (14). 
Blok za ublažavanje udarca (20) u skladu s patentnim zahtjevom 1, naznačen time, da su prvi i drugi završetak (24, 26) najmanje jednog kanala (22) okomito poravnani u ravnini stijenke (14).
An impact pad (20) according to claim 1 wherein the first and second ends (24, 26) of the at least one channel (22) are vertically displaced in the plane of the sidewall (14). 
Blok za ublažavanje udarca (20) u skladu s patentnim zahtjevom 1, naznačen time, da su prvi i drugi završetak (24, 26) najmanje jednog kanala (22) postavljeni okomito u ravnini stijenke (14).
An impact pad (20) according to any of claims 1 or 3 to 8, wherein at least a pair of channels (22) is provided and wherein the pair either converge or diverge towards their second ends (26). 
Blok za ublažavanje udarca (20) u skladu s bilo kojim od sljedećih patentnih zahtjeva: 1 ili 3 do 8, naznačen time, da se u njemu nalazi najmanje jedan par kanala (22), a taj par kanala se međusobno približava ili udaljava u smjeru njihovih drugih završetaka (26).
Cement composition that comprising dopamelanin and/or its precursors and/or its analogous and/or its derivatives, as an additive in a maximum percentage of 30% of the cement, this additive substitutes the water of the capillary nets; said cement mixture posses a water/cement relation of 0.2 to 0.4, and optionally it can contain different gravel and sand proportions; said cement mixture generates strong chemical bonds, a higher scouring resistance, at least of the 28% and a higher elastic resistance of the concrete, of at least 50%, therefore its cracking in early stages is significantly lower in comparison with conventional concrete. 
Cementni sastav, naznačen time, da sadrži dopamelanin kao aditiv u maksimalnom postotku od 30% od cementa, gdje taj aditiv zamjenjuje mrežu kapilarne vode, dok spomenuta cementna smjesa ima odnos voda/cement od 0,2 do 0,4, te opcijski može sadržavati šljunak i pijesak u različitim mjerama, pri čemu spomenuta cementna smjesa generira jake kemijske veze, veći otpor na ispiranje i to najmanje 28% kao i veći elastični otpor betona od najmanje 50%, te se stoga pucanje u ranim stadijima značajno smanjuje u usporedbi s konvencionalnim betonom.
A foam layer (6) according to claim 3, characterised in that the lines (13) have an equal distance from each other. 
Sloj pjene (6) prema zahtjevu 3, naznačen time da linije (13) imaju jednaku međusobnu udaljenost.
A foam layer (6) according to any of claims 1 to 4, characterised in that the slits (17) are positioned according to a staggered pattern, whereby the slits (17) along adjacent lines (13) are offset in their longitudinal direction. 
Sloj pjene (6) prema bilo kojem zahtjevu od 1 do 4, naznačen time da su prorezi (17) postavljeni u cik-cak rasporedu, pri čemu su prorezi (17) uzduž susjednih linija (13) pomaknuti u njihovom uzdužnom smjeru.
A foam spring (1) according to claim 10 or 11, characterised in that the holes (3) are mainly diamond-shaped. 
Pjenaste opruge (1) prema zahtjevu 10 ili 11, naznačene time da su otvori (3) uglavnom oblika dijamanta.
A pyrazole compound represented by the formula (I) or its salt: wherein 
Spoj pirazola predstavljenog formulom (I) ili njegova sol:
A process for producing a pyrazole compound represented by the formula (I) or its salt: wherein 
Postupak za proizvodnju spoja pirazola predstavljenog formulom (I) ili njegova sol:
which comprises reacting a pyrazole compound represented by the formula (II) or its salt: wherein R1, R2, R4, R5 and R6 are as defined in claim 1, with a compound represented by the formula (III): wherein Hal is halogen, and R3 and A are as defined above. 
je metilsulfonil, A je -CH(Me)- koji sadrži reagirajući spoj pirazola predstavljenog formulom (II) ili njegova sol: [image] pri čemu su R1, R2, R4, R5 i R6 definirani u patentnom zahtjevu 1, sa spojem predstavljenim formulom (III):
A method for controlling undesired plants or inhibiting their growth, which comprises applying a herbicidally effective amount of the pyrazole compound or its salt as defined in Claim 1 or 2 to the undesired plants or to a place where they grow. 
Postupak za kontroliranje nepoželjnih biljaka ili sprječavanje njihovog rasta, naznačen time, da isti sadrži primjenu herbicidno učinkovite količine spoja pirazola ili njegove soli definirane u patentnom zahtjevu 1 ili 2 na nepoželjne biljke ili na mjesto njihovog rasta.
Rb is selected from the group consisting of H, alkyl, and F; 
Rb je odabran iz skupine koju čine H, alkil i F;
R4a is selected from the group consisting of H and alkyl; 
a je odabran iz skupine koju čine H i alkil;
is selected from the group consisting of H, alkyl, and R4b; 
je odabran iz skupine koju čine H, alkil i R4b;
The compound of claim 1, wherein R is N(R1)-A-G-Q-J, R1 is H and A-G-Q-J together form H, or together form a functional group selected from the group consisting of 
Spoj prema zahtjevu 1, naznačen time, da R je N (R1)-A-G-Q-J, R1 je H i A-G-Q-J zajedno tvore H, ili zajedno tvore funkcionalnu skupinu odabranu iz skupine koju čine:
A compound of any one of claims 1-8 for use in treating, inhibiting or preventing a bacterial infection(s) including infections caused by multi-drug resistant strains of Staphyloccocus aureus, Streptococcus pneumoniae, Mycobacterium tuberculosis and Enterococci, Clostridium difficile, Propionibacterium acnes, Bacteroides fagiles, Neisseria gonorrhoeae, Branhamella catarrhalis, Haemophilus influenzae, E. coli, Pseudomonas aeruginosa, Proteus vulgaris, Klebsiella pneumonia, and Chlamydia trachomatis. 
Spoj prema bilo kojem od zahtjeva 1 do 8, naznačen time, da se upotrebljava za liječenje, inhibiciju ili prevenciju bakterijskih infekcija uključujući infekcije koje su uzrokovane sojevima bakterija otpornima na veći broj lijekova, kako slijedi: Staphyloccocus aureus, Streptococcus pneumoniae, Mycobacterium tuberculosis i Enterococci, Clostridium difficile, Propionibacterium acnes, Bacteroides fagiles, Neisseria gonorrhoeae, Branhamella catarrhalis, Haemophilus influenzae, E.coli, Pseudomonas aeruginosa, Proteus vulgaris, Klebsiella pneumonia i Chlamydia trachomatis.
The compound of any one of claims 1-8 in combination with a pharmaceutically effective amount of an additional therapeutic agent for use in the treatment of bacterial infection. 
Spoj prema bilo kojem od zahtjeva 1 do 8, naznačen time, da se upotrebljava u kombinaciji s farmaceutski učinkovitom količinom dodatnog terapeutskog sredstva u svrhu liječenja bakterijske infekcije.
A compound of Formula (I): or a stereoisomer or pharmaceutically acceptable salt form thereof 
Spoj Formule (I): [image] ili njegov stereoizomer ili farmaceutski prihvatljiv oblik soli.
A pharmaceutical composition comprising a compound of claim 1 and one or more additional active ingredients. 
Farmaceutska smjesa koja sadrži spoj prema zahtjevu 1 te jednu ili više dodatnih djelatnih tvari.
A pharmaceutical composition according to claim 3 wherein the one or more additional active ingredients is selected from integrin antagonists, steroids, immunosuppressants, antihistamines, non-steroidal anti-asthmatics, non-steroidal anti-inflammatory agents (NSAIDS), cycloxygenase-2 (COX-2) inhibitors, inhibitors of phosphodiesterase type IV (PDE-IV), antagonists of the chemokine receptors, cholesterol lowering agents, anti-diabetic agents, preparations of interferons, antiviral compounds, anti-metabolites and cytotoxic cancer chemotherapeutic agents. 
Farmaceutska smjesa prema zahtjevu 3 gdje se jedna ili više dodatnih djelatnih tvari izabire između antagonista integrina, steroida, imunosupresiva, antihistaminika, ne-steroidnih anti-astmatika, ne-steroidnih protu-upalnih lijekova (NSAIDS), inhibitora ciklo-oksigenaze-2 (COX-2), inhibitora fosfodiesteraze tip IV (PDE-IV), antagonista receptora kemokina, sredstava za snižavanje kolesterola, antidijabetika, pripravaka interferona, antivirusnih spojeva, antimetabolita i citotoksičnih kemoterapijskih sredstava protiv raka.
A pharmaceutical composition according to claim 3 wherein the one or more additional active ingredients is selected from antagonists for selectins, ICAMs and VLA-4; FK-506 type immunosuppressants; H1-histamine antagonists; non-steroidal anti-asthmatics selected from b2-agonists, leukotriene antagonists, and leukotriene biosynthesis inhibitors; non-steroidal anti-inflammatory agents (NSAIDs) selected from propionic acid derivatives, acetic acid derivatives, fenamic acid derivatives, biphenylcarboxylic acid derivatives, oxicams, salicylates, and pyrazolones; cholesterol lowering agents selected from HMG-COA reductase inhibitors, sequestrants, nicotonic acid, fenofibric acid derivatives; anti-diabetic agents selected from sulfonylureas, biguanides, a-glucosidase inhibitors and glitazones; and preparations of interferons selected from interferon alpha-2a, interferon-2B, interferon alpha-N3, interferon beta-1a, interferon beta-1b and interferon gammy-1b. 
Farmaceutska smjesa prema zahtjevu 3 gdje se jedna ili više dodatnih djelatnih tvari izabire između antagonista za selektine, ICAM i VLA-4; FK-506 tip imunosupresiva; H1-histamin antagonista; ne-steroidnih anti-astmatika izabranih između b2-agonista, antagonista leukotriena, i inhibitora sinteze leukotriena; ne-steroidnih protu-upalnih lijekova (NSAIDS) izabranih između derivata propionske kiseline, derivata octene kiseline, derivata fenaminske kiseline, derivata bifenilkarboksilne kiseline, oksikama, salicilata i pirazolona; sredstava za snižavanje kolesterola izabranih između inhibitora reduktaze HMG-COA, sekvestranata, nikotinske kiseline, derivata fenofibrične kiseline; antidijabetika izabranih između sulfonilurea, bigvanida, inhibitora a-glukozidase i glitazona; i pripravaka interferona izabranih između interferona alfa-2a, interferona-2B, interferona alfa-N3, interferona beta-1a, interferona beta-1b i interferona gama-1b.
A pharmaceutical composition according to claim 3 wherein the one or more additional active ingredients is selected from acetaminophen, aspirin, codeine, fentaynl, ibuprofen, indomethacin, ketorolac, morphine, naproxen, phenacetin, piroxicam, sufentanyl, sunlindac, interferon alpha, caffeine, simethicone, aluminum or magnesium hydroxide, phenylephrine, phenylpropanolamine, pseudophedrine, oxymetazoline, ephinephrine, naphazoline, xylometazoline, propylhexedrine, levodesoxy-ephedrine, codeine, hydrocodone, caramiphen, carbetapentane and dextramethorphan. 
Farmaceutska smjesa prema zahtjevu 3 gdje se jedna ili više dodatnih djelatnih tvari izabire između acetaminofena, aspirina, kodeina, fentanila, ibuprofena, indometacina, ketorolaka, morfija, naproksena, fenacetina, piroksikama, sufentanila, sunlindaka, interferona alfa, kofeina, simetikona, aluminijevog ili magnezijevog hidroksida, fenilefrina, fenilpropanolamina, pseudofedrina, oksimetazolina, efinefrina, nafazolina, ksilometazolina, propilheksedrina, levodeoksi-efedrina, kodeina, hidrokodona, karamifena, karbetapentana i dekstrametorfana.
A compound for use according to claim 13 or claim 14, or a composition for use according to claim 13, for use in treating a disorder selected from spondyloarthropathies, osteoarthritis, aneurysm, fever, cardiovascular effects, Crohn's disease, congestive heart failure, autoimmune diseases, HIV-infection, HIV-associated dementia, psoriasis, idiopathic pulmonary fibrosis, renal fibroses, cystic fibrosis, transplant arteriosclerosis, physically- or chemically-induced brain trauma, neuropathic pain, inflammatory bowel disease, alveolitis, ulcerative colitis, systemic lupus erythematosus, nephrotoxic serum nephritis, glomerulonephritis, asthma, multiple sclerosis, arthrosclerosis, rheumatoid arthritis, restenosis, transplant rejection, multiple myeloma, colorectal cancer, hepatocellular cancer and other cancers. 
Spoj za uporabu prema zahtjevu 13 ili zahtjevu 14, ili smjesa za uporabu prema zahtjevu 13, za uporabu u liječenju poremećaja izabranog između spondiloartropatija, osteoartritisa, aneurizme, vrućice, kardiovaskularnih događaja, Crohnove bolesti, kongestivnog zatajenja srca, autoimunih bolesti, HIV-infekcije, HIV-povezane demencije, psorijaze, idiopatske plućne fibroze, fibroze bubrega, cistične fibroze, arterioskleroze transplantanta, fizički ili kemijski inducirane traume mozga, neuropatske boli, upalne bolesti crijeva, alveolitisa, ulceroznog kolitisa, sistemskog lupus eritematosus, nefrotoksičnog serumskog nefritisa, glomerulonefritisa, astme, multiple skleroze, artroskleroze, reumatoidnog artritisa, restenoze, odbacivanja transplantata, multiplog mijeloma, kolorektalnog raka, hepatocelularnog raka i drugih vrsta raka.
A compound for use according to claim 13 or claim 14, or a composition for use according to claim 13, for use in treating inflammatory diseases. 
Spoj za uporabu prema zahtjevu 13 ili zahtjevu 14, ili smjesa za uporabu prema zahtjevu 13, za uporabu u liječenju upalnih bolesti.
A compound for use according to claim 13 or claim 14, or a composition for use according to claim 13, for use in treating cystic fibrosis. 
Spoj za uporabu prema zahtjevu 13 ili zahtjevu 14, ili smjesa za uporabu prema zahtjevu 13, za uporabu u liječenju cistične fibroze.
A compound for use according to claim 13 or claim 14, or a composition for use according to claim 13, for use in treating interstitial lung disease. 
Spoj za uporabu prema zahtjevu 13 ili zahtjevu 14, ili smjesa za uporabu prema zahtjevu 13, za uporabu u liječenju intersticijske bolesti pluća.
Device according to claim 1, characterised in that said grip portion (114) consists of a flat surface that at least partially surrounds said containment portion (112). 
Naprava u skladu s patentnim zahtjevom 1, naznačena time što se navedeni dio za hvatanje (114) sastoji od ravne površine koja u najmanju ruku djelomično okružuje navedeni dio za držanje (112).
Device according to claim 1, characterised in that an inner surface of said containment portion (112) is coated by overmoulding with a layer (120) of non-stick material in the manufacturing step. 
Naprava u skladu s patentnim zahtjevom 1, naznačena time što je unutarnja površina navedenog dijela za držanje (112) obložena prekalupljenim slojem (120) neljepljivog materijala u koraku proizvodnje.
Use of the Compound of formula for the preparation of a medicament for use in the treatment of hereditary hemochromatosis. Use of Compound I for the preparation of a medicament for the treatment of an excess of iron in a patient having hereditary hemochromatosis. 
Uporaba, naznačena time, da se spoj formule I: [image] koristi za proizvodnju lijeka za uporabu u liječenju prekomjernog željeza kod pacijenta koji ima nasljednu hemokromatozu (HH), pri čemu to liječenje obuhvaća:
Capsule according to claim 1, wherein the flexible sheet-shaped perforate and/or porous material is a flexible foil, such as a polymeric film, at least partly provided with a plurality of exit openings (23). 
Kapsula prema zahtjevu 1, naznačena time da je savitljivi perforirani i/ili porozni materijal neka savitljiva folija, kao što je neki polimerni film i da barem u nekom dijelu ima više izlaznih otvora (23).
Capsule according to any one of claims 1-5, wherein the lid (9) is sufficiently strong and sufficiently stiff to resist, in use, piercing by lid piercing means of an apparatus. 
Kapsula prema bilo kojem od zahtjeva 1-5, naznačena time da je poklopac (9) dovoljno čvrst i dovoljno krut da se prilikom uporabe odupre prodiranju probojnih elemenata uređaja za bušenje poklopca.
Capsule according to claim 7, wherein the lid (9) and the annular sealing member (31) are of the same material. 
Kapsula prema zahtjevu 7, naznačena time da su poklopac (9) i prstenasti brtveni element (31) od istog materijala.
Capsule according to claim 7, wherein the annular sealing member (31) is of a resilient material such as a plastic, for instance PE or a rubber. 
Kapsula prema zahtjevu 7, naznačena time da je prstenasti brtveni element (31) napravljen od nekog elastičnog materijala kao što je plastika, na primjer PE ili guma.
Capsule according to claim 2, wherein the flexible foil is a multilayer foil. 
Kapsula prema zahtjevu 2, naznačena time da je ta savitljiva folija višeslojna folija.
A communication cable splice box (40, 50, 60, 80) with a waterproof shrinkable rubber tube device comprising: 
Spojna kutija za komunikacijski kabel (40, 50, 60, 80) sa vodonepropusnom napravom od skupljajuće gumene cijevi koja sadrži: zaštitni pokrov (62, 82);
a first hollow cylindrical tube (52, 63, 83) formed on the cable entry board (51, 61, 81); 
prvu šuplju cilindričnu cijev (52, 63, 83) koja je oblikovana na ploči za ulaz kabela (51, 61, 81);
The communication cable splice box (40, 50, 60, 80) according to claim 3, characterized in that the first fixture (93A, 98) is buried in the cable entry board (51, 61, 81). 
Spojna kutija za komunikacijski kabel (40, 50, 60, 80) prema zahtjevu 3, naznačena time da je prvi držač (93A, 98) sadržan u ploči za ulaz kabela (51, 61, 81).
The communication cable splice box (40, 50, 60, 80) according to claim 3, characterized in that the first fixture (93A, 98) is integratedly formed on the cable entry board (51, 61, 81). 
Spojna kutija za komunikacijski kabel (40, 50, 60, 80) prema zahtjevu 3, naznačena time da je prvi držač (93A, 98) integralno oblikovan na ploči za ulaz kabela (51, 61, 81).
The communication cable splice box (40, 50, 60, 80) according to claim 3 characterized by further comprising a supporting portion (93, 97) for connecting the first fixture (93A, 98) with the second fixture (93B, 100). 
Spojna kutija za komunikacijski kabel (40, 50, 60, 80) prema zahtjevu 3 naznačena time da dodatno sadrži nosivi dio (93, 97) za spajanje prvog držača (93A, 98) sa drugim držačem (93B, 100).
The communication cable splice box (40, 50, 60, 80) according to claim 8, characterized in that the second fixture(93B, 100) is in one piece with the supporting portion (93, 97). 
Spojna kutija za komunikacijski kabel (40, 50, 60, 80) prema zahtjevu 8, naznačena time da je drugi držač (93B, 100) u jednom komadu sa nosivim dijelom (93, 97).
The communication cable splice box (40, 50, 60, 80) according to claim 8, characterized in that the second fixture (93B, 100) is mechanically jointed with the supporting portion(93, 97). 
Spojna kutija za komunikacijski kabel (40, 50, 60, 80) prema zahtjevu 8, naznačena time da je drugi držač (93B, 100) mehanički spojen sa nosivim dijelom(93, 97).